Volume 18, Number 5—May 2012
Invasive Haemophilus influenzae Serotype e and f Disease, England and Wales
Medscape, LLC is pleased to provide online continuing medical education (CME) for this journal article, allowing clinicians the opportunity to earn CME credit.
This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education through the joint sponsorship of Medscape, LLC and Emerging Infectious Diseases. Medscape, LLC is accredited by the ACCME to provide continuing medical education for physicians.
Medscape, LLC designates this Journal-based CME activity for a maximum of 1 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
All other clinicians completing this activity will be issued a certificate of participation. To participate in this journal CME activity: (1) review the learning objectives and author disclosures; (2) study the education content; (3) take the post-test with a 70% minimum passing score and complete the evaluation at www.medscape.org/journal/eid; (4) view/print certificate.
Release date: April 16, 2012; Expiration date: April 16, 2013
Upon completion of this activity, participants will be able to:
• Analyze the epidemiology of Hie and Hif
• Distinguish the risk for mortality associated with invasive cases of Hie and Hif
• Evaluate invasive infection with Hie and Hif among children
• Evaluate invasive infection with Hie and Hif among older adults.
Shannon O’Connor, Technical Writer/Editor, Emerging Infectious Diseases. Disclosure: Shannon O’Connor has disclosed no relevant financial relationships.
Charles P. Vega, MD, Health Sciences Clinical Professor; Residency Director, Department of Family Medicine, University of California, Irvine. Disclosure: Charles P. Vega, MD, has disclosed no relevant financial relationships.
Disclosures: Shamez N. Ladhani, MRCPCH, PhD, has disclosed the following relevant financial relationships: served as an advisor or consultant for GSK, Pfizer, SPMSD, Baxter; served as a speaker or a member of a speakers bureau for GSK, Pfizer, SPMSD, Baxter (all on behalf of St. Georges University of London, but has not received any personal remuneration for these activities). Sarah Collins; Anna Vickers, MD; Carina Crawford; and Mary E. Ramsay, FFPHM, have disclosed no relevant financial relationships. David J. Litt has disclosed the following relevant financial relationships: received grants for clinical research from GSK. Mary P.E. Slack, FRCPATH, has disclosed the following relevant financial relationships: served as a speaker or a member of a speakers’ bureau for GSK, Pfizer; received grants for clinical research from GSK, Pfizer; received support for travel to scientific meetings from GSK, Pfizer, Merck.